The pharmaceutical industry has undergone a significant transformation in its approach to marketing, with social media becoming a critical channel for engaging healthcare professionals (HCPs), patients, and other stakeholders. In 2025, this evolution has accelerated, driven by technological advancements. Globally, social media now serves as a cornerstone for pharmaceutical marketing strategies, offering unprecedented opportunities for targeted communication, patient education, and HCP brand building (awareness, engagement, conversion). And this growth is taking place in Canada as well, with companies becoming more comfortable running campaigns within the regulatory framework. However, the landscape is not without challenges.
Engagement Metrics and Platform Performance
The social media landscape for pharmaceutical companies in 2025 presents a complex picture of challenges and opportunities. Recent (global) data reveals significant declines in engagement rates across major platforms, with Facebook experiencing a 36% drop, Instagram 16%, TikTok 34%, and Twitter (X) suffering the most substantial decrease at 48%. Despite these trends, pharmaceutical companies continue to recognize the value of social media, with 75% actively leveraging these platforms to enhance their marketing efforts globally.
The global Pharma and Healthcare Social Media market has shown remarkable growth, valued at USD 15,300.36 million in 2024 and projected to reach USD 18,054.5 million in 2025. Looking further ahead, the market is expected to expand to USD 67,864.1 million by 2033, growing at an impressive CAGR of 18.0% during the forecast period 2025–2033. These figures underscore the industry's commitment to social media despite engagement challenges, reflecting a recognition of its fundamental importance in modern marketing strategies.
Understanding which platforms resonate with specific audiences is crucial for pharmaceutical marketers. Although Meta is being used more and more to effectively reach HCPs, LinkedIn and Twitter have emerged as effective channels for professional engagement with HCPs, while Facebook and Instagram better serve patient-focused initiatives. This differentiation is supported by usage statistics showing that over 75% of U.S. healthcare professionals actively use social media for professional purposes, while 90% of patients consult online health information before making medical decisions.
Pharmaceutical companies are increasingly adopting a multi-channel approach, with 58% of marketers utilizing Facebook and 40% identifying it as a top ROI driver despite overall engagement declines. Short-form video and image content have proven most effective, with platforms like Instagram seeing healthcare-related posts receive over 4.5 billion likes per month.
Patient-Centric Content Strategies
Pharmaceutical companies—particularly in the U.S—continue to recognize the critical importance of patient-centric content strategies in their social media marketing efforts. This approach focuses on creating educational content that addresses patient needs and concerns while maintaining regulatory compliance. Patient demand is driving this shift, with 60% of individuals expressing a desire to receive health information through social media channels.
Successful patient-centric strategies emphasize disease awareness, treatment options, and patient support resources—a distinction that remains especially important under Canadian regulations. Pharmaceutical companies that have adopted innovative approaches have reported tangible results such as a 23% improvement in medication adherence rates.
Campaigns like Boehringer Ingelheim's "Create Your Change" for type 2 diabetes which garnered 22 million impressions and increased website traffic by 71% and Pfizer's "Get Old" campaign which humanized the drug development process demonstrate the potential impact of patient-centered storytelling. While these examples stem from U.S. initiatives, they offer useful inspiration for Canadian marketers, who must carefully tailor similar efforts to meet Health Canada’s regulatory standards.
In the Canadian market, branded consumer (patient) campaigns can be highly successful even within regulatory guidelines. While direct promotional claims are not permitted beyond the brand name, strategic campaigns can still deliver strong engagement and results. By anchoring creative development around the right patient insights and leveraging unbranded engagement tactics—such as storytelling videos—brands can meaningfully connect with patients while remaining compliant. At Healthwise Creative, we have seen firsthand that well-designed branded patient campaigns can drive significant reach, patient education, and loyalty, even within the more stringent Canadian framework.
Engaging HCPs effectively through social media requires a different approach than patient-focused campaigns. In 2025, around 70% of physicians actively engaged in social networking for professional purposes, with approximately 87% of physicians reporting using Twitter for professional discussion. This high adoption rate presents significant opportunities for pharmaceutical companies to connect with HCPs.
Although content targeted at HCPs should be scientifically rigorous, concise, and focused on clinical efficacy in other regions this is not possible in Canada. Social media platforms are considered public space, and all direct-to-consumer (DTC) advertising regulations apply—even when content is intended for HCPs. As a result, detailed clinical, scientific, or product-specific information must be housed behind a secure, gated platform requiring appropriate credential verification. Social media strategies should therefore prioritize sparking engagement, using insight-driven messaging to invite HCPs to gated educational resources, professional events, or disease awareness initiatives.
Even within branded parameters, effective HCP social media engagement relies on insights—crafting content that connects with professional needs and encourages action toward gated educational resources.
At Healthwise Creative, we have successfully designed Canadian social media campaigns that drive HCPs to gated educational platforms. Whether reaching broader general practice audiences in therapeutic areas like IBS or engaging rare disease specialists with insight-driven engagement strategies, these campaigns demonstrate that strong HCP interest and action are achievable—provided the approach prioritizes a clear value exchange while remaining compliant, and seamless pathways to secure, credentialed content.
Navigating the regulatory landscape remains one of the most significant challenges for pharmaceutical companies on social media. Regulatory bodies such as the FDA and EMA continue to develop guidelines to manage healthcare-related social media communications, ensuring compliance while maintaining transparency. In Canada, pharmaceutical communications must comply with Health Canada’s Food and Drugs Act, the Food and Drug Regulations, and the ethical standards set by Innovative Medicines Canada, governed by PAAB and ASC.
Pharmaceutical companies must ensure all social media content undergoes review to meet regulatory requirements including providing balanced information where permitted, avoiding misleading claims, and establishing clear processes for adverse events reporting—even for those mentioned on social media channels. Over 50% of healthcare professionals express concerns about regulatory scrutiny when using social media for professional interaction, highlighting the need for robust governance frameworks and clear internal guidance.
Successful strategies involve implementing effective monitoring to track social media engagement and ensure adverse events are reported according to regulatory requirements, in real-time. Companies that develop strong social media policies, train employees on compliance best practices and maintain close collaboration between marketing, medical, and regulatory teams are better positioned to navigate this complex environment while maintaining an active, compliant social media presence.
